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INTRODUCTION 
Schizophrenia (SCH) is a major psychiatric disease. 
The underlying psychopathological mechanisms are not 
thoroughly understood. Recent working hypotheses on 
the etiology of SCH discuss numerous molecular 
mechanisms; those hypotheses require an extensive 
multidisciplinary research, the results of which would 
either confirm or discard them. One of the hypotheses 
discusses the disturbance of membrane phospholipids 
and cytokynes in SCH that might result in anomalies of 
oxidative and anti-oxidative processes (Nadalin et al. 
2008, Buretić-Tomljanović et al. 2008, Akyol et al. 
2002, Arolt et al. 2000, Arvindakshan et al. 2003, 
Bakeret al. 1996). The changes of membrane phosphor-
lipids are related not only to the intensity of symptoms, 
but also to the specific clinical representations of SCH 
(Peet et al. 2002, Puri et al. 2000, Richardson et al. 
2000). The results of numerous studies indicate the 
important role of lipid molecules in normal and 
disturbed neurotransmitter system upon which the 
current pharmacotherapy of SCH is established 
(Faroogui et al. 2000, Faroogui et al. 2000, Skosnik et 
al. 2003, Yao & van Kammen 2004, Sampath et al. 
2005). Biochemical mechanism of the development of 
SCH, based on the lipid metabolism is not fully under-
stood, although the biology of phospholipid molecules 
is completely established, and the genetic basis of the 
enzymes that regulate their metabolisms are determined 
and defined. 
Another hypothesis suggests the disturbance in 
protein synthesis in SCH. The facts that could be 
assembled to create this hypothesis were mostly 
obtained from the Human Genome Project (HGP) 
(Lander et al. 2001), which has, following the secondary 
principle of Darwinism (Cziko et al. 1995), pointed out 
84 important features in SCH. Genetic and epigenetic 
varieties of the genes involved in the processes of signal 
transduction, transcription, translation, all converge 
towards protein syntesis rate (PSR), that is being 
considered as common final pathway, supposedly 
responsible for genetic determination of SCH. CPSR 
hypothesis offers explanation for 96.7% of major 
findings in SCH, and reveals the connection of several 
important hypotetic models. The hypotheses implícate 
that SCH is easy to prevent and treat. In spite of all the 
advantages of CPSR hypothesis, a caution is necessary 
until all the findings are tested and proved. 
The above mentioned hypotheses establish connec-
tion with another hypothesis of SCH as a neuro-
developmental disease. In early foetal development, the 
individual cerebral and craniofacial morphogenetic 
process occurs. Namely, documented differences in 
craniofacial appearance of schizophrenic patients and 
control group are connected to developmental disorders 
of cranio-facial morphogenesis, and are tightly linked 
with early cerebral development disorders (Arnold et al. 
1999, DeLisiet al. 1999, Gharaibeh et al. 2000). By 
detailed study of facial dysmorphogenesis it may be 
possible to assemble enough information and enable the 
explanation of the nature and time of occurrence of this 
neurodevelopmental disorder. The multitude of factors 
influencing early cerebral development, environmental 
factors included, underlines the importance of regional 
morphometric studies (Selemon et al. 2001). There are 
no published data on craniofacial dysmorphology of 
schizophrenic patients in Croatia (Buretić-Tomljanović 
et al. 2009). Furthermore, volumetric changes of brain 
in schizophrenic patients has not been thoroughly 
researched worldwide, while in Croatia, these data are 
nonexistent (Gilbert et al. 2001, Verma et al. 2009, Win 
et al. 2008, Rusch et al. 2008, Zetzscheet al. 2008, 
Okugawa et al. 2007, Uchidaet et al. 2008).  
The etiology of SCH is still not fully established. 
The above mentioned hypotheses, as well as recent 
results of numerous research projects dealing with the 
etiology of SCH offer many new potentially beneficial 
therapeutic options. 
 
DOPAMINE THEORY OF THE 
ETIOLOGY OF SCHIZOPHRENIA AND 
THERAPEUTIC POSSIBILITIES 
Hyperactivity of dopamine within mezolymbic 
system causes positive symptoms (hallucinations and 
delusions), cognitive symptoms (thought disorders) and 
aggressive and hostile symptoms (especially if 
serotonin-mediated control of dopamine is also 
disturbed, which is the case in patients with impulse 
control disruption) (Natesan et al. 2006).  
Theoretically, the increase of dopamine in meso-
cortical dopamine pathway could improve negative, 
cognitive and affective symptoms of SCH. However, 
since an abundance of dopamine already exists 
everywhere else within the brain, and in mesolymbic 
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dopamine pathway, any further increase of dopamine in 
that pathway would increase the intensity of positive 
symptoms. This gives rise to a therapeutic dilemma: is 
there a way to increase dopamine in mesocortical 
pathway, and simultaneously decrease the activity of 
dopamine in mesolymbic dopamine pathway. Atypical 
antipsychotic have provided solution of this therapeutic 
dilemma (Takahashi et al. 2006).  
The function of dopamine in SCH might be much 
more complex than just „too high“ in mesolymbic areas 
and “too low” in mesocortical areas. Instead, it is 
plausible to characterize the dopaminergic neurons as 
“out of tune” or “chaotic”. Similar phenomenon might 
exist within mesolymbic dopamine system, with one 
group of mesolymbic dopaminergic neurons being „out 
of tune“ as well as hyperactive, causing thus positive 
symptoms, and the other set of mesolymbic dopamine-
ergic neurons being also „out of tune“ and hypoactive, 
mediating some of the negative symptoms and dysfunc-
tional reward mechanisms (reward, pleasure, motive-
tion, interest). This idea is supported by the observation 
that patients treated with antipsychotic drugs, particu-
larly with conventional antipsychotics, might experience 
worsening of the negative symptoms, and might develop 
a state of „neurolepsy“, with the symptoms remarkably 
similar to the negative symptoms of SCH. Since the 
density of D2 receptors in prefrontal cortex isn't very 
high, this also implicates the possibility of deficient 
function within mesolymbic dopamine system which 
causes inadequacy of reward mechanisms that are 
presented as anhedonia, substance abuse, but may also 
be presented as negative symptoms: lack of rewarding 
social interactions, lack of motivation and interest.  
The level of dopamine in nigrosriatal and meso-
lymbic pathways in SCH is normal, but the admini-
stration of D2 blockers (conventional antipsychotics) 
causes dopamine deficiency (Remington et al. 2006). 
The activity of dopamine in hypothalamic-hypophysal 
projections in SCH is also normal, but D2 blockers 
cause dopamine deficiency, therefore the inhibition of 
proalactin is no longer possible (Remington et al. 2006). 
The theory on increased level of prolactin being the 
cause of SCH, was deducted through observation of the 
effects of antipsychotic drug phenothiazine which 
blocks the dopamine activity by binding to postsynaptic 
D2 receptors in dopamine pathways (Kessler et al. 
2006). However, there are many „holes“ in this theory. 
It offers no explanation of the fact that the symptoms 
are alleviated only after several weeks, while binding to 
the receptors occurs immediately; neither has it 
provided clues regarding the fact that in order to achieve 
desired effect, the activity of the receptors needs to be 
down regulated below their normal level of activity. 
Those facts give rise to the question whether the 
problem lies in the excess of dopamine or in the 
hypersensitivity of the receptors. We now know that 
both facts are true. 
Recent research indicate that dopamine activity is 
increased only in mid-regions of the brain (mesolymbic 
pathway), with the consequential dopamine hypoactivity 
in prefrontal cortex. This sequence of events is further 
supported by the observation that blocking the 
dopamine receptors causes regression of positive 
symptoms (hallucinations, disorganized speech...), but 
not the regression of negative symptoms (social 
withdrawal, apathy) that are linked to reduced activity 
in prefrontal cortex (Clinton et al. 2005).  
The deficit of working memory, i.e. short-term 
memory in schizophrenic patients is yet another proof of 
dopamine deficiency in prefrontal cortex. 
Schizophrenic patients have not only increased level 
of dopamine and increased number and sensitivity of 
their receptors within CNS, but also an increase of D3 
receptors in peripheral blood. By the use of molecular 
biology techniques it was possible to show that human 
peripheral blood lymphocytes express several types of 
dopamine receptors in their membranes (D3, D4, and 
D5). It has been speculated that the lymphocytic 
dopamine receptors mirror the activity of brain 
dopamine receptors (Ilan et al. 2001).  
A study had been conducted with the aim to measure 
by densitometry the level of mRNA for dopamine 
receptors in lymphocytes of schizophrenic patients and 
age and sex matched healthy individuals to establish 
whether those receptors may serve as peripheral 
markers of the disease. Significant increase in level of 
mRNA D3 receptors, but no increase of D4, was found 
in schizophrenic patients (the increase of D3 dopamine 
receptors was found also post-mortem in the brains of 
both treated and untreated schizophrenic patients) (Ilan 
et al. 2001). No antipsychotic treatment had any effect 
upon this finding, since there was no increase in 
untreated patients. The study suggests lymphocytic D3 
receptors mRNA to be employed as a marker for 
identification and follow up for SCH. In conclusion, the 
results of this study suggest that the level of 
lymphocytic D3 receptor mRNA represents a reliable 
peripheral marker for SCH and an important tool in 
early diagnostics (Ilan et al. 2001).  
 
THE ROLE OF GLUTAMATE IN THE 
ETIOLOGY OF SCHIZOPHRENIA AND 
NEW THERAPEUTIC POSSIBILITIES 
Glutamates are the principal excitatory neuro-
transmitter in CNS that can excitate and activate any 
CNS neuron. It's an amino acid, employed as a building 
block in protein biosynthesis (Coyle et al. 2006).  
Currently, extensive research of the hypothesis that 
links hypofunction of NMDA receptors in certain gluta-
mate pathways and positive symptoms of SCH is being 
undertaken (Coyle et al. 2006, Bennet et al. 2005, Scarr 
et al. 2005). Cortex – brain stem cortical projections 
communicate with mesolymbic dopaminergic pathway 
through GABA interneurons in ventral tegmental area 
(VTA). Excitatory glutamate stimulation of interneuron 
NMDA receptors causes the release of GABA that 
usually mediates the inhibition of dopamine release in 
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mesolymbic dopamine pathway. Therefore, the des-
cending glutaminergic pathway under normal circum-
stances acts as a brake in mesolymbic dopaminergic 
pathway. If the NMDA receptor residing on GABA 
interneurons becomes hypoactive, no descending effect 
of tonic inhibition will occur, the net result being 
hyperactivity of the described dopaminergic pathway. 
These are the outlines of the theory for the biology of 
mesolymbic dopamine hyperactivity that is linked to the 
positive symptoms of psychosis. 
The cortex – brain stem projection communicates 
directly with the mesocortical dopaminergic pathway in 
VTA (therefore, there are no GABA interneurons here), 
and causes tonic excitation in normal circumstances 
(i.e., it acts as an accelerator of mesocortical dopamine 
neurons). If the NMDA receptors in the cortex – brain 
stem projection become hypoactive, the tonic excitation 
is lost, and mesocortical dopaminergic pathway 
becomes hypoactive, potentially offering an explanation 
for cognitive, negative and affective symptoms of SCH 
(Pralong et al. 2002).  
Hypofunction of NMDA receptors within five 
glutamate pathways may potentially account for 
positive, negative, affective and cognitive symptoms; 
also, it provides an explanation for deregulation of 
dopamine due to hypofunciton of NMDA receptors, 
resulting in hyperactivity in mesolymbic dopaminergic 
pathway for positive symptoms and hypoactivity in 
mesocortical dopaminergic pathway for cognitive, 
negative and affective symptoms of SCH. Many of the 
currently standing theories founded on the genetic basis 
of SCH are shifting their attention upon NMDA 
receptors in search of new drugs for the treatment of 
SCH (Javitt et al. 2006). 
 
THE ROLE OF SEROTONIN IN THE 
ETIOLOGY OF SCHIZOPHRENIA AND 
THERAPEUTIC POSSIBILITIES 
Recently, a lot of attention has been given to the 
abnormalities of serotonin system that might be connec-
ted with the development of SCH. The discovery that 
hallucinogen agents like indolamine and phenetilamine 
that exert their actions on CNS via 5HT2 receptors, a 
conclusion has been made that the hallucinations in 
SCH might occur through similar mechanism (Reynolds 
et al. 2004). In the studies of the actions of hallucinogen 
substances, two brain regions are in focus: locus 
coeruleus and cortex. In these areas the hallucinogens 
act through 5HT2A receptors and increase the transmis-
sion of glutamate. In prefrontal cortex 5HT2A receptors 
also stimulate the release of glutamate. This effect can 
be reversed by the inhibitory group II/III metabotropic 
glutamate agonists that act presynaptically, and by 
antagonists of AMPA glutamate receptors which act 
postsinaptically, on non-NMDA receptors. This is a 
confirmation of the link between serotonin and 
glutamate systems.  
The following observations have been made: a) 
serotonins receptors are involved in psychomymetic and 
psychotogenic properties of hallucinogens; b) there is an 
increase in number of cortical 5-HT2A and 5-HT1A 
receptors in the brain of schizophrenic patients; c) 5-
HT2A and 5-HT1A receptors have major role in the 
onset and treatment of side-effects of atypical anti-
psychotics; d) there are firm evidence of the link 
between 5-HT2A receptors gene polymorphism and the 
development of SCH; e) trophic role of serotonin in 
neurodevelopment may be impaired in SCH; f) 5-HT2A 
receptor mediated activation of prefrontal cortex may be 
insufficient in schizophrenic patients; g) serotonergic 
and dopaminergic neurotransmitter pathways in the 
brain are intertwined and may both be impaired in SCH 
(Aghajanian et al. 2000). 
The research showed that schizophrenic patients 
have significantly higher concentration of platelet sero-
tonin than their healthy counterparts. Hyperserotonina-
emia is more often seen in schizophrenic patients with 
predominantly paranoid than in the patients with 
predominantly non-paranoid symptoms. Extremely high 
levels of platelet serotonin in chronically ill schizo-
phrenic patients may reflect the progression of the 
disease. High levels of platelet serotonin were not 
related either to the seasonal or diurnal variations of 
platelet serotonin or to the age of the patients. The study 
showed higher level of platelet serotonin in male than in 
female patients. In the course of treatment with both 
classical and atypical antipsychotic drugs no change of 
the concentration of platelet serotonin has been obser-
ved, irrespective of the type of SCH as well as of 
baseline pre-treatment level of platelet serotonin. The 
results imply the change in the peripheral serotonin 
system in schizophrenic patients (Muck-Šeler et al. 2005). 
PET-scan study was conducted with the aim to 
measure the binding of serotonin to the 5-HT2A 
receptors in the non-treated schizophrenic patients and 
healthy age-matched controls. The results showed 
reduced density of serotonin receptors in older subjects 
from both groups. There were no significant differences 
between sexes in the group of healthy subjects. A 
significant decrease of serotonin binding in frontal 
cortex was observed in the brains of schizophrenic 
patients. These results show that reduced number of 
serotonin receptors in SCH occurs in the early stages of 
the disease, prior to the exposure to neuroleptic drugs 
(Ngan et al. 2000). 
 
THE ROLE OF ACETILCHOLINE  
(ACH) IN THE ETIOLOGY OF 
SCHIZOPHRENIA AND  
THERAPEUTIC POSSIBILITIES 
Post mortal and neuroimmaging studies showed 
reduced number of M1 and M4 muscarine receptors in 
schizophrenic patients in several key loci, including 
nucleus caudatus and putamen, hippocampus, anterior 
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and dorsal cingular cortex, and prefrontal cortex, while 
there were no changes in the number of M2 and M3 
receptors. Relative hyperactivity of cholinergic system 
may contribute to the negative symptoms of SCH, but 
also to the gravity of productive symptoms (Thomas et 
al. 2003).  
As far as the acetyl-choline metabolizing enzymes 
are concerned, there are proofs of reduced concentration 
of choline-acetyltransferase in the pons, while the 
concentration of the same enzyme is increased in hippo-
campus, caudate nuclei, putamen and nucleus accum-
bens in schizophrenic patients. Several pharmacological 
studies were very important for the understanding of the 
role of cholinergic system in the pathophisiology of 
SCH. In those studies anti-cholinergic drugs or acetyl-
choline agonists were given to the schizophrenic 
patients, and the effects were observed and quantified. 
The results showed that choline-esterase inhibitors 
improve cognitive functions of the patients, while 
muscarine antagonists improve negative, but also 
intensify positive symptoms of SCH – this finding was 
interpreted as an increased cholinergic activity. 
As far as cholinergic interaction with other 
neurotransmitter systems in SCH is concerned, there is 
an important discovery of muscarine receptors in 
dopaminergic neurons in striatum, substantia nigra and 
cortex; VTA also releases dopamine when stimulated by 
acetyl-choline. Some scientists speculate that SCH may 
be caused by excessive activation of neurons in 
pedunculopontine and latero-dorsal tegmental nuclei, 
followed by the activation of dopaminergic neurons. 
There are proofs that schizophrenic patients have 
shorter REM latency, which may also be a consequence 
of muscarine "supersensitivity" (Thomas et al. 2003).  
 
NEURODEGENERATIVE HYPOTHESIS 
OF SCHIZOPHRENIA  
Neuroimmaging studies of the schizophrenic 
patient’s brains show functional and structural 
abnormalities, giving rise to the assumption that the 
observed neurodegenerative process followed by 
progressive loss of neuronal functions might be 
ongoing, integral part of the development of SCH (Bota 
et al. 2005, Cavelier et al. 1995).  
Neurodegenerative theories of SCH assume that the 
progressive loss of neuronal functions, either by the loss 
of dendrites, by the destruction of synapses, or by 
neuronal death might be the cause of the symptoms and 
progression of SCH. The causes of neurodegeneration 
might be: genetic programming of neuronal or synaptic 
destruction, prenatal exposure to anoxia, toxins, infec-
tions, malnutrition, resulting in foetal insults; dopamine-
mediated neurodegeneration and/or glutamate-mediated 
excytotoxicity that may initially cause positive symp-
toms, but following neuronal death, residual negative 
symptoms pervade (Bota et al. 2005).  
There are many proofs of the loss of cortical grey 
matter, reduction of amygdale, hippocampus, and 
reduction in frontal and temporal lobes in schizophrenic 
patients. Dopamine is a probable culprit in this case, 
since it is well documented that the excess of dopamine 
in certain conditions causes cell death. Namely, 
dopamine inhibits mitochondrial respiration; the 
reduced activity of mitochondrial cytochrome-C oxidase 
has been shown in schizophrenic patients. The energetic 
deficit may reduce the activity of DAT (dopamine 
transporter) and keep the neurotransmitter in 
extracellular liquid longer (Cavelier et al. 1995). 
Yet another mechanism that contributes to the 
cellular oxidative stress lies in the catabolism of 
dopamine; with the help of MAO, hydrogen-peroxide is 
generated and linked to non-bound iron molecules, 
causing oxidative damage of the cells. 
Pivotal idea that offers the explanation for 
neurodegeneration in SCH, as well as the explanation 
for resistance to the pharmacotherapy, claims that 
neurodegenerative events in SCH may be mediated by 
one kind of excessive activity of glutamate called 
excytotoxicity. Excytotoxic hypothesis of SCH assumes 
that the neurons degenerate as a result of excessive 
excitatory neurotransmission of glutamate neurons. The 
process of excytotoxicity is not exclusive for 
neurodegeneration in SCH, it is also employed as 
explanation for neurodegeneration in many different 
neurological and psychiatric conditions, including 
Alzheimer’s disease and other degenerative dementias, 
Parkinson’s disease, amyotrophic lateral sclerosis 
(ALS), and even stroke (Alphs et al. 1989). 
 
NEURODEVELOPMENTAL 
HYPOTHESIS OF SCHIZOPHRENIA 
It is believed that early brain dysmorphogenesis may 
cause facial dysmorphogenesis as well. Since there is an 
anomaly of early brain development in SCH, it is 
believed that the same anomaly may be mirrored in 
facial dysmorphogenesis. Early anthropometric research 
showed minor variations of facial morphology in 
schizophrenic patients, but the development of digital 
technology and tri-dimensional lasers surface scanner 
enabled much more profound research of this subject. 
3D MRI morphometric technique has also been 
successful in the research of dysmorphogenesis 
(Johnson et al. 2006). In a number of researches many 
deviations of facial morphology were established, and 
they were significantly more often present in 
schizophrenic patients: mouth, lips and chin are 
narrower and pushed backwards, upper portion of a 
face, mandible and basis of the skull are wider, palate is 
short and wide. Eyes, orbits and cheeks are placed 
laterally, while the upper orbital margin is protruding, 
nose is small, lips are fuller, forehead is low, middle and 
lower sections of the face are elongated. Some authors 
describe the sculls of schizophrenic patients as 
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brachichephalic. All the changes of facial morphology 
indicate towards tight relationship of facial and cerebral 
development. Deviant facial morphology of schizo-
phrenic patients represents an external expression of all 
the changes occurring during foetal development, and 
results in established schizophrenic process (Arnold et 
al. 1999, DeLisiet al. 1999, Gharaibeh, et al. 2000, 
Buckley et al. 2008).  
Morphometric changes of the brain show the 
reduction of gray matter’s volume, increased volume of 
cerebro-spinal fluid, dilatation of brain chambers, while 
the results on white matter volume show no consistency. 
Abnormalities are more marked in frontal and temporal 
regions (Gilbert et al. 2001, Verma et al. 2009, Win et 
al. 2008, Rusch et al. 2008, Zetzscheet et al. 2008, 
Okugawa et al. 2007, Uchidaet et al. 2008). The brains 
of treated patients show increased volume of basal 
ganglia (Davatzikos et al. 2005). Some sex differences 
were also found (Davatzikos et al. 2005). 
 
THE ROLE OF CENTRAL PROTEIN 
SYNTHESIS IN THE ETIOLOGY OF 
SCHIZOPHRENIA 
Using the results obtained in Human Genome 
Project (HGP) (Lander et al. 2001), new insigts 
regarding the etiology of SCH were searched for. As 
previously mentioned, genetic and epigenetic varieties 
of the genes included in the processes of signal 
transduction, transcription, and translation converge 
towards the curve for protein synthesis (protein 
synthesis rate, PSR), as an expected final pathway that 
is supposed to be responsible for genetic determination 
of SCH; this model also reveals interconnection of 
several important hypothetic models. Hypotheses 
implicate that SCH is easy to prevent and treat, partly 
by immunization against neurotrophic viruses, partly by 
development of new drugs that would specifically 
enhance central protein synthesis (Moises et al. 2002). 
It is therefore possible that SCH is caused by the 
reduced cerebral protein synthesis, including entire 
human proteome. The reduced protein synthesis may be 
caused by environmental (e.g. viruses) and genetic 
agents (Moises et al. 2002). Environmental component 
is explained by epigenetic variety of the genes during 
intrauterine development or early in life, as well as by 
reduction of CPSR due to reduced growth factors, 
hormones, ageing and latent viral infections that are 
known to reduce the level of PSR. 
CPSR hypothesis accounts for about 96.7% of major 
discoveries in SCH, it reveals the relationship among 
previously independent discoveries, and integrates 
several very important hypotheses. 
Depending on the rate, the reduction of CPSR 
expectedly causes prodromal, depressive and negative 
symptoms first. Severe defficiency of CPSR may further 
cause positive, disorganized, and finally catatonic 
symptoms. Reduction of CPSR that would cause 
schizophrenic symptoms may be the consequence of 
reduced quantity of growth factors or hormons, or may 
develop after acute, latent or re-activated viral infection. 
Re-activation of a latent virus is probably responsible 
for majority of the acute episodes of SCH. Significant 
deficit of CPSR causes neuronal degeneration. 
Increase of CPSR during remission will initiate 
neural remodelling. Increase of CPSR happens either 
spontaneously, or is induced by some medicines, such 
as insulin, prolactin or by electrostimulation. Either 
way, the regeneration of neuronal network is incomplete 
and some defects persist (Moises et al. 2002). 
Antipsychotic mechanisms of antipsychotic drugs 
are linked to CPSR. There are observations showing the 
common feature of all the typical and atypical 
antipsychotic drugs, such as clozapine, olanzapine, 
risperidone, amisulpride, ziprazidone and zotepine, 
which is increase of CPSR (Moises et al. 2002, 
McLaughlin et al. 2003). 
Electrostimulation and electroconvulsive therapy – 
which has proven itself efficient in grave catatonic 
schizophrenia – increases the level of insulin and 
protein synthesis. 
 
PHOSPHOLIP THEORY OF 
SCHIZOPHRENIA 
Long chain polyunsaturated fatty acids (LC-PUFA) 
are essential for normal development of the brain 
structures and its functions. It is therefore plausible that 
a disturbance of their metabolism participates in the 
aetiology of SCH, depression and other mental 
disorders. Biochemical mechanism of SCH is based 
upon the metabolism of lipids, but is not fully clarified, 
although the biology of phospholipid molecules is well 
known, and the enzymes involved in the regulation of 
their metabolism are entirely cloned (Feldberg et al. 
1976). 
The reduced content of polyunsaturated fatty acids 
has been observed post mortem in the membranes of 
cerebral tissue, peripheral tissues, e.g. red blood cells 
(Herken et al. 2001) and skin fibroblasts and plasma 
(Horrobin et al. 1989) of schizophrenic patients. 
Disorder of multiple neurotransmitters in SCH 
(dopaminergic, serotonergic, noradrenergic, gluta-
minergic, GABA-ergic) supports the phospholipid 
hypothesis which gives central role in the 
pathophysiology of this disease to neuronal membranes 
and numerous processes that take place there. 
Many studies demonstrated the deficiency of 
arachidonic acid (AA) and fatty acids in the membranes 
of peripheral and central cells of schizophrenic patients, 
that is caused by increased activity of the PLA2 
(phospholipase) enzyme. Next event is the increase in 
release of LC-PUFA from membrane phospholipids, 
increased production of anti-inflammatory cytokines 
(AA derivates), increased peroxidation of lipids, and 
creation of free radicals, and imbalance of release and 
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re-uptake of fatty acids in membrane phospholipid 
molecules (Ross et al. 1997). 
The research is directed towards the potential of 
unsaturated fatty acids in treatment of SCH (Freeman 
2006, Richardson 2006). 
 
DISCUSSION 
The cause of SCH has still not been fully elucidated. 
The development of new technologies has enabled 
important research into putative causes of this disease. 
In order to improve diagnostic and therapy protocols, 
the exact pathophysiological mechanisms are being 
researched. Based on the current research data, it is 
necessary to cluster schizophrenic patients according to 
their phenotypes; there are still many areas for further 
research, including and underlining the procedure of 
routine follow-up of schizophrenic patients, starting 
with the conception, in persons with increased risk for 
SCH. Prenatal, perinatal and postnatal properties of 
SCH may help to establish early diagnosis of the 
disease. 
There are many different theories and hypotheses on 
possible links among some neurotransmitters, genes and 
environmental factors and SCH. In dopamine 
hypothesis of SCH, the disturbed level of dopamine is 
thought to be the main cause of SCH. It is considered 
that the dopamine activity is increased in mid-region of 
a brain (mesolymbic pathway) (Natesan et al. 2006), 
and reduced in prefrontal cortex (Clinton et al. 2005). 
The dopamine receptors are also being scrutinized, and 
are found to be increased not only in CNS, but also in 
peripheral blood lymphocytes (Ilan et al. 2001). It is 
well established that high level of dopamine leads to 
cell death by inhibition of mitochondrial respiration and 
by reduction of mitochondrial cytochrome-C oxidase 
activity in schizophrenic patients (Cavelier et al. 1995). 
Glutamate hypothesis of SCH deals with a cluster of 
pathological mechanisms related to glutamatergic 
signalling. In early stages of the research, this 
hypothesis was based on clinical, neuropathological, 
later also genetic findings; all of them indicated towards 
hypofunction of glutamatergic signalling trough NMDA 
receptors (Coyle et al. 2006, Bennet et al. 2005, Scarr et 
al. 2005). Metabotropic glutamate receptors mGluR2 
and mGluR3 are thought to play an important role in the 
pathophysiology of SCH. There are proofs that 
schizophrenic patients have a significant increase of 
glutamate-carboxipeptidase II and decrease of mGluR3 
protein in dorsolateral prefrontal cortex, while the level 
of mGluR2 protein remains unchanged. Pre-clinical 
studies show that the activation of mGlu5 or mGlu2/3 
receptors may be an efficient strategy for the alleviation 
of cognitive deficiencies that are caused by the NMDA 
receptors-mediated reduction of neurotransmission. A 
number of valid, genetically based theories of the 
etiology of SCH are shifting their focus on NMDA 
receptors as a likely candidate for new SCH treatment 
drugs (Javitt et al. 2006). 
The discovery that some hallucinogenic drugs, e.g. 
indolamine and phenetilamine act upon CNS via 5-HT2 
receptors, led to the conclusion that hallucinations in 
SCH might be caused by the same mechanism (Rey-
nolds et al. 2004). The increased number of 5-HT2A 
and 5-HT1A cortical receptors has been observed in the 
brains of schizophrenic patients. The polymorohism of 
5-HT2A receptor gene has also been confirmed; that 
may indicate insufficient 5-HT2A receptor - mediated 
activation of prefrontal cortex (Aghajanian et al. 2000). 
Current research show that schizophrenic patients have 
significantly increased level of platelet serotonin, com-
pared to healthy individuals, the finding that is more 
pronounced in patients with predominantly paranoid 
symptoms of the disease (Muck-Šeler et al. 2005). 
Pharmacological studies propelled the research on 
the involvement of cholinergic system in the patho-
physiology of SCH; the anticholinergic or acetyl-
choline agonists were administered and the changes in 
the patients were studied. Postmortal and neuro-
immaging studies showed reduced number of M1 and 
M4 muscarine receptors in schizophrenic patients in 
crucial loci, such as caudate nucleus, putamen, 
hippocampus, anterior and posterior cingular cortex, and 
prefrontal cortex (Thomas et al. 2003). 
Neurodegenerative theory of SCH assumes that the 
progressive loss of neuronal function either by the loss 
of dendrites, by the destruction of synapses or neuronal 
death may be the cause of the symptoms and 
progression of SCH (Bota et al. 2005, Cavelier et al. 
1995). The progressive course of the disease supports 
the neurodegenerative theory of SCH, as well as the 
observation that successful antipsychotic treatment may 
vary significantly in the course of the disease. Those 
hypotheses are being explained by the excessive 
glutamate action that causes excitotoxicity. 
Neurodevelopmental hypothesis of SCH indicates 
that the development of the brain and face are closely 
connected, so that any disturbance in the brain 
development may be mirrored in facial morphology 
(Arnold et al. 1999, DeLisiet al. 1999, Gharaibeh,et al. 
2000, Buckley et al. 2008). The reduction of gray matter 
volume and the increase of cerebrospinal fluid volume 
have been observed in schizophrenic patients. Also, in 
schizophrenic patients certain changes in facial 
morphology have been observed, and their appearance 
shows statistically significant regularity of occurrence. 
New working hypotheses of the ethiology of SCH 
operate with a number of molecular mechanisms, the 
most researched being the disruption in central protein 
synthesis as a cause of SCH. Membrane phospholipids 
are also being extensively researched. 
The disrupted protein synthesis hypothesis is based 
on the research results from human genome project. 
Both environmental and genetic factors can cause 
reduced protein synthesis. This is the only hypothesis 
that accounts for nearly all of the phenotypic properties 
of SCH, and is still being extensively tested (Moises et 
al. 2002, McLaughlin et al. 2003). 
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New studies also showed the importance of the 
membrane phospholipids’ metabolism disorders 
(Herken et al. 2001, Horrobin et al. 1989). The results 
have defined the reduction of fatty acids incorporation 
and neuronal membrane catabolism enhancement. The 
underlying mechanism is abnormally high activity of 
phospholypase A2 (PLA2) enzyme which leads to 
increased release of LC-PUFA from membrane 
phospholipids; this event causes increased synthesis of 
inflammatory mediators, increased lipid peroxidation 
and release of free radicals, as well as imbalance 
between release and re-integration of fatty acids in 
membranes of phospholipid molecules. 
 
CONCLUSIONS 
There are many hypotheses on the development of 
SCH. None of them fully explains all of the phenotypic 
properties of SCH, but all of them offer new therapeutic 
options. The closest to elucidate all of the properties of 
the disease is the central protein synthesis reduction 
hypothesis, but it is still a subject of extensive control 
research. Unequivocal definition of the ethiology of 
SCH would contribute significantly to the diagnosis and 
treatment of SCH. 
All the above mentioned hypotheses clearly show 
the necessity for collaborative efforts of genetic 
scientists, psychologists and psychiatrists in the 
treatment of schizophrenic patients. Definition of the 
phenotypic groups of SCH might result in the creation 
of type –specific diagnostic and treatment algorithms. 
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